Age, ECOG PS, menopausal status, visceral illness, bone metastasis, CDK4/6i type, number of metastatic locations, endocrine sensitivity or resistance status, dosage decrease, and concurrent usage of PPIs were all considered in the univariate analysis (Table 5). Here, CDK4 is linked to bone metastasis.